secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001193125-24-056852
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene expands Rett syndrome gene therapy trial, adds high-dose cohort
-------------------------------------------------------------------------

- Cohort 1 expanded from 5 to 8 patients; staggered dosing removed for parallel enrollment.
- New Cohort 2 with higher dose (3×10^15 vector genomes) added; first patient dosing expected Q2 2024.
- Third patient dosed in Cohort 1; no serious adverse events or overexpression-related toxicity observed.
- Interim Cohort 1 data expected Q4 2024; Cohort 2 data expected H2 2025.
- Targeted immunosuppression (rituximab, sirolimus) added for Cohort 2 to prevent AAV immune responses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000119312524056852/0001193125-24-056852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000119312524056852/d754656d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-056852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer